|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stintzing S, Modest DP, Rossius L, Lerch
MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U,
Al-Batran SE, Heintges T, et al: FOLFIRI plus cetuximab versus
FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3):
A post-hoc analysis of tumour dynamics in the final RAS wild-type
subgroup of this randomised open-label phase 3 trial. Lancet Oncol.
17:1426–1434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Camargo FD, Gokhale S, Johnnidis JB, Fu D,
Bell GW, Jaenisch R and Brummelkamp TR: YAP1 increases organ size
and expands undifferentiated progenitor cells. Curr Biol.
17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu FX, Meng Z, Plouffe SW and Guan KL:
Hippo pathway regulation of gastrointestinal tissues. Annu Rev
Physiol. 77:201–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS,
Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, et al: Significant
association of oncogene YAP1 with poor prognosis and cetuximab
resistance in colorectal cancer patients. Clin Cancer Res.
21:357–364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang
X, Zhang X, Zhang F, Chen H, Liu Y, et al: Interplay of mevalonate
and hippo pathways regulates RHAMM transcription via YAP to
modulate breast cancer cell motility. Proc Natl Acad Sci USA.
111:E89–E98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sorrentino G, Ruggeri N, Specchia V,
Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio
R, Piazza S, et al: Metabolic control of YAP and TAZ by the
mevalonate pathway. Nat Cell Biol. 16:357–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma J, Xue Y, Liu W, Yue C, Bi F, Xu J,
Zhang J, Li Y, Zhong C and Chen Y: Role of activated Rac1/Cdc42 in
mediating endothelial cell proliferation and tumor angiogenesis in
breast cancer. PLoS One. 8:e662752013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van Cutsem E, Kohne CH, Hitre E, Zaluski
J, Chien Chang CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mullen PJ, Yu R, Longo J, Archer MC and
Penn LZ: The interplay between cell signalling and the mevalonate
pathway in cancer. Nat Rev Cancer. 16:718–731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu
IC, Lin SR and Wang JY: Activating KRAS mutations and
overexpression of epidermal growth factor receptor as independent
predictors in metastatic colorectal cancer patients treated with
cetuximab. Ann Surg. 251:254–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF,
NRAS, and PIK3CA mutations on the efficacy of cetuximab
plus chemotherapy in chemotherapy-refractory metastatic colorectal
cancer: A retrospective consortium analysis. Lancet Oncol.
11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiu CF, Chang YW, Kuo KT, Shen YS, Liu
CY, Yu YH, Cheng CC, Lee KY, Chen FC, Hsu MK, et al: NF-κB-driven
suppression of FOXO3a contributes to EGFR mutation-independent
gefitinib resistance. Proc Natl Acad Sci USA. 113:E2526–E2535.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng
Z, Zhao L, Peyman G, Ouyang H, Jiang W, et al: Mutant Gq/11 promote
uveal melanoma tumorigenesis by activating YAP. Cancer Cell.
25:822–830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang KC, Yeh YT, Nguyen P, Limqueco E,
Lopez J, Thorossian S, Guan KL, Li YJ and Chien S: Flow-dependent
YAP/TAZ activities regulate endothelial phenotypes and
atherosclerosis. Proc Natl Acad Sci USA. 113:11525–11530. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee J, Lee I, Han B, Park JO, Jang J, Park
C and Kang WK: Effect of simvastatin on cetuximab resistance in
human colorectal cancer with KRAS mutations. J Natl Cancer Inst.
103:674–688. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong X, Nguyen HT, Chen Q, Zhang R, Hagman
Z, Voorhoeve PM and Cohen SM: Opposing activities of the Ras and
Hippo pathways converge on regulation of YAP protein turnover. EMBO
J. 33:2447–2457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He C, Lv X, Hua G, Lele SM, Remmenga S,
Dong J, Davis JS and Wang C: YAP forms autocrine loops with the
ERBB pathway to regulate ovarian cancer initiation and progression.
Oncogene. 34:6040–6054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He C, Mao D, Hua G, Lv X, Chen X,
Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al: The
Hippo/YAP pathway interacts with EGFR signaling and HPV
oncoproteins to regulate cervical cancer progression. EMBO Mol Med.
7:1426–1449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pocobelli G, Newcomb PA, Trentham-Dietz A,
Titus-Ernstoff L, Hampton JM and Egan KM: Statin use and risk of
breast cancer. Cancer. 112:27–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Freeman SR, Drake AL, Heilig LF, Graber M,
McNealy K, Schilling LM and Dellavalle RP: Statins, fibrates, and
melanoma risk: A systematic review and meta-analysis. J Natl Cancer
Inst. 98:1538–1546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen
Q, Leng W, Chen L, Tang Q and Bi F: CD44 acts through RhoA to
regulate YAP signaling. Cell Signal. 26:2504–2513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Farwell WR, Scranton RE, Lawler EV, Lew
RA, Brophy MT, Fiore LD and Gaziano JM: The association between
statins and cancer incidence in a veterans population. J Natl
Cancer Inst. 100:134–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cauley JA, McTiernan A, Rodabough RJ,
LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg
CD and Chlebowski RT: Women's Health Initiative Research Group:
Statin use and breast cancer: Prospective results from the Women's
Health Initiative. J Natl Cancer Inst. 98:700–707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee J, Hong YS, Hong JY, Han SW, Kim TW,
Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, et al: Effect of
simvastatin plus cetuximab/irinotecan for KRAS mutant
colorectal cancer and predictive value of the RAS signature
for treatment response to cetuximab. Invest New Drugs. 32:535–541.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
